Based on its recent analysis of microarrays in molecular diagnostics (MDx), Frost & Sullivan recognizes Akonni Biosystems, Inc. with the 2017 North America Frost & Sullivan Award for New Product Innovation. Akonni’s integrated MDx system, TruDiagnosis®, is revolutionizing the point-of-care molecular testing market by enabling target detection from a variety of sample types. TruDiagnosis® is powered by TruArray®, a patented 3D gel-drop microarray technology for sample screening that instantly indicates the presence of disease markers in real time. Frost & Sullivan believes that Akonni is properly positioned to serve the precision medicine revolution.
“TruDiagnosis® offers rapid, reliable multiplexed analysis at a lower overall cost per array,” reports Frost & Sullivan Senior Research Analyst Sanchari Chatterjee Maity. “The company modified this platform by replacing the traditional glass substrate with a cost-effective plastic film substrate for printing arrays without requiring functionalized coatings. Akonni also enhanced the manufacturing process for reel-to-reel manufacturing of arrays on film to generate greater cost efficiencies.”
TruDiagnosis® consists of Akonni’s proprietary TruDx® Imagers, TruArray® Assays, and TruTip® sample prep kits and includes nucleic acid extraction as well as fully-automated gridding and data analysis software for patient reporting. The platform serves a range of applications such as pharmacogenomics, chronic human diseases (cancer), infectious diseases, extensive drug-resistant tuberculosis, upper respiratory infections, viral encephalitis, and hospital-acquired infections.
Click here for the full multimedia experience of this release – http://bit.ly/2wJbPPQ